ID   CREB1_HUMAN             Reviewed;         327 AA.
AC   P16220; P21934; Q6V963; Q9UMA7;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   07-OCT-2020, sequence version 3.
DT   18-JUN-2025, entry version 262.
DE   RecName: Full=Cyclic AMP-responsive element-binding protein 1;
DE            Short=CREB-1;
DE            Short=cAMP-responsive element-binding protein 1;
GN   Name=CREB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2142528; DOI=10.1073/pnas.87.14.5258;
RA   Berkowitz L.A., Gilman M.Z.;
RT   "Two distinct forms of active transcription factor CREB (cAMP response
RT   element binding protein).";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5258-5262(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2196176; DOI=10.1002/j.1460-2075.1990.tb07434.x;
RA   Yoshimura T., Fujisawa J., Yoshida M.;
RT   "Multiple cDNA clones encoding nuclear proteins that bind to the tax-
RT   dependent enhancer of HTLV-1: all contain a leucine zipper structure and
RT   basic amino acid domain.";
RL   EMBO J. 9:2537-2542(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1966745;
RA   Waeber G., Meyer T.E., Hoeffler J.P., Habener J.F.;
RT   "Diversification of cyclic AMP-responsive enhancer binding proteins-
RT   generated by alternative exon splicing.";
RL   Trans. Assoc. Am. Physicians 103:28-37(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2974179; DOI=10.1126/science.2974179;
RA   Hoeffler J.P., Meyer T.E., Yun Y., Jameson J.L., Habener J.F.;
RT   "Cyclic AMP-responsive DNA-binding protein: structure based on a cloned
RT   placental cDNA.";
RL   Science 242:1430-1433(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1831258; DOI=10.1093/nar/19.15.4290;
RA   Short M.L., Manohar C.F., Furtado M.R., Ghadge G.D., Wolinsky S.M.,
RA   Thimmapaya B., Jungmann R.A.;
RT   "Nucleotide and derived amino-acid sequences of the CRE-binding proteins
RT   from rat C6 glioma and HeLa cells.";
RL   Nucleic Acids Res. 19:4290-4290(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=15579595; DOI=10.1530/rep.1.00036;
RA   Huang X., Zhang J., Lu L., Yin L., Xu M., Wang Y., Zhou Z., Sha J.;
RT   "Cloning and expression of a novel CREB mRNA splice variant in human
RT   testis.";
RL   Reproduction 128:775-782(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-8.
RX   PubMed=8381074; DOI=10.1210/endo.132.2.8381074;
RA   Meyer T.E., Waeber G., Lin J., Beckmann W., Habener J.F.;
RT   "The promoter of the gene encoding 3',5'-cyclic adenosine monophosphate
RT   (cAMP) response element binding protein contains cAMP response elements:
RT   evidence for positive autoregulation of gene transcription.";
RL   Endocrinology 132:770-780(1993).
RN   [9]
RP   INTERACTION WITH HBV PROTEIN X (MICROBIAL INFECTION).
RX   PubMed=1827531; DOI=10.1126/science.1827531;
RA   Maguire H.F., Hoeffler J.P., Siddiqui A.;
RT   "HBV X protein alters the DNA binding specificity of CREB and ATF-2 by
RT   protein-protein interactions.";
RL   Science 252:842-844(1991).
RN   [10]
RP   INTERACTION WITH HTLV-1 TAX (MICROBIAL INFECTION).
RX   PubMed=1386673; DOI=10.1073/pnas.89.15.7070;
RA   Zhao L.J., Giam C.-Z.;
RT   "Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator,
RT   Tax, enhances CREB binding to HTLV-I 21-base-pair repeats by protein-
RT   protein interaction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7070-7074(1992).
RN   [11]
RP   PHOSPHORYLATION AT SER-119, AND MUTAGENESIS OF SER-119.
RX   PubMed=8065343; DOI=10.1128/mcb.14.9.6107-6116.1994;
RA   Matthews R.P., Guthrie C.R., Wailes L.M., Zhao X., Means A.R.,
RA   McKnight G.S.;
RT   "Calcium/calmodulin-dependent protein kinase types II and IV differentially
RT   regulate CREB-dependent gene expression.";
RL   Mol. Cell. Biol. 14:6107-6116(1994).
RN   [12]
RP   PHOSPHORYLATION AT SER-119.
RX   PubMed=7608156; DOI=10.1074/jbc.270.27.15979;
RA   Lee H.-J.J., Mignacca R.C., Sakamoto K.M.;
RT   "Transcriptional activation of egr-1 by granulocyte-macrophage colony-
RT   stimulating factor but not interleukin 3 requires phosphorylation of cAMP
RT   response element-binding protein (CREB) on serine 133.";
RL   J. Biol. Chem. 270:15979-15983(1995).
RN   [13]
RP   PHOSPHORYLATION AT SER-119.
RX   PubMed=9829964; DOI=10.1074/jbc.273.49.32377;
RA   Du K., Montminy M.;
RT   "CREB is a regulatory target for the protein kinase Akt/PKB.";
RL   J. Biol. Chem. 273:32377-32379(1998).
RN   [14]
RP   PHOSPHORYLATION AT SER-119.
RX   PubMed=9770464; DOI=10.1073/pnas.95.21.12202;
RA   De Cesare D., Jacquot S., Hanauer A., Sassone-Corsi P.;
RT   "Rsk-2 activity is necessary for epidermal growth factor-induced
RT   phosphorylation of CREB protein and transcription of c-fos gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:12202-12207(1998).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH CRTC1.
RX   PubMed=14536081; DOI=10.1016/j.molcel.2003.08.013;
RA   Conkright M.D., Canettieri G., Screaton R., Guzman E., Miraglia L.,
RA   Hogenesch J.B., Montminy M.;
RT   "TORCs: transducers of regulated CREB activity.";
RL   Mol. Cell 12:413-423(2003).
RN   [16]
RP   SUMOYLATION AT LYS-271 AND LYS-290, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF LYS-141; LYS-271 AND LYS-290.
RX   PubMed=12552083; DOI=10.1073/pnas.0337412100;
RA   Comerford K.M., Leonard M.O., Karhausen J., Carey R., Colgan S.P.,
RA   Taylor C.T.;
RT   "Small ubiquitin-related modifier-1 modification mediates resolution of
RT   CREB-dependent responses to hypoxia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:986-991(2003).
RN   [17]
RP   INTERACTION WITH CRTC3.
RX   PubMed=14506290; DOI=10.1073/pnas.1932773100;
RA   Iourgenko V., Zhang W., Mickanin C., Daly I., Jiang C., Hexham J.M.,
RA   Orth A.P., Miraglia L., Meltzer J., Garza D., Chirn G.-W., McWhinnie E.,
RA   Cohen D., Skelton J., Terry R., Yu Y., Bodian D., Buxton F.P., Zhu J.,
RA   Song C., Labow M.A.;
RT   "Identification of a family of cAMP response element-binding protein
RT   coactivators by genome-scale functional analysis in mammalian cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12147-12152(2003).
RN   [18]
RP   INTERACTION WITH CRTC2.
RX   PubMed=15454081; DOI=10.1016/j.cell.2004.09.015;
RA   Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G.,
RA   Jeffries S., Guzman E., Niessen S., Yates J.R. III, Takemori H.,
RA   Okamoto M., Montminy M.;
RT   "The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive
RT   coincidence detector.";
RL   Cell 119:61-74(2004).
RN   [19]
RP   INTERACTION WITH TSSK4, PHOSPHORYLATION AT SER-119, AND MUTAGENESIS OF
RP   SER-119.
RX   PubMed=15964553; DOI=10.1016/j.bbrc.2005.05.157;
RA   Chen X., Lin G., Wei Y., Hexige S., Niu Y., Liu L., Yang C., Yu L.;
RT   "TSSK5, a novel member of the testis-specific serine/threonine kinase
RT   family, phosphorylates CREB at Ser-133, and stimulates the CRE/CREB
RT   responsive pathway.";
RL   Biochem. Biophys. Res. Commun. 333:742-749(2005).
RN   [20]
RP   INTERACTION WITH ARRB1.
RX   PubMed=16325578; DOI=10.1016/j.cell.2005.09.011;
RA   Kang J., Shi Y., Xiang B., Qu B., Su W., Zhu M., Zhang M., Bao G., Wang F.,
RA   Zhang X., Yang R., Fan F., Chen X., Pei G., Ma L.;
RT   "A nuclear function of beta-arrestin1 in GPCR signaling: regulation of
RT   histone acetylation and gene transcription.";
RL   Cell 123:833-847(2005).
RN   [21]
RP   PHOSPHORYLATION AT SER-119 BY SGK1, AND INTERACTION WITH SGK1.
RX   PubMed=15733869; DOI=10.1016/j.febslet.2005.01.040;
RA   David S., Kalb R.G.;
RT   "Serum/glucocorticoid-inducible kinase can phosphorylate the cyclic AMP
RT   response element binding protein, CREB.";
RL   FEBS Lett. 579:1534-1538(2005).
RN   [22]
RP   INTERACTION WITH PPRC1.
RX   PubMed=16908542; DOI=10.1128/mcb.00585-06;
RA   Vercauteren K., Pasko R.A., Gleyzer N., Marino V.M., Scarpulla R.C.;
RT   "PGC-1-related coactivator: immediate early expression and characterization
RT   of a CREB/NRF-1 binding domain associated with cytochrome c promoter
RT   occupancy and respiratory growth.";
RL   Mol. Cell. Biol. 26:7409-7419(2006).
RN   [23]
RP   CHROMOSOMAL TRANSLOCATION WITH EWSR1, AND ASSOCIATION WITH ANGIOMATOID
RP   FIBROUS HISTIOCYTOMA.
RX   PubMed=17724745; DOI=10.1002/gcc.20491;
RA   Antonescu C.R., Dal Cin P., Nafa K., Teot L.A., Surti U., Fletcher C.D.,
RA   Ladanyi M.;
RT   "EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous
RT   histiocytoma.";
RL   Genes Chromosomes Cancer 46:1051-1060(2007).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   PHOSPHORYLATION AT SER-257 BY HIPK2, MUTAGENESIS OF SER-257, AND
RP   INTERACTION WITH HIPK2.
RX   PubMed=20573984; DOI=10.1091/mbc.e10-01-0015;
RA   Sakamoto K., Huang B.-W., Iwasaki K., Hailemariam K., Ninomiya-Tsuji J.,
RA   Tsuji Y.;
RT   "Regulation of genotoxic stress response by homeodomain-interacting protein
RT   kinase 2 through phosphorylation of cyclic AMP response element-binding
RT   protein at serine 271.";
RL   Mol. Biol. Cell 21:2966-2974(2010).
RN   [28]
RP   INTERACTION WITH TOX3, AND MUTAGENESIS OF SER-119.
RX   PubMed=21172805; DOI=10.1242/jcs.068759;
RA   Dittmer S., Kovacs Z., Yuan S.H., Siszler G., Kogl M., Summer H.,
RA   Geerts A., Golz S., Shioda T., Methner A.;
RT   "TOX3 is a neuronal survival factor that induces transcription depending on
RT   the presence of CITED1 or phosphorylated CREB in the transcriptionally
RT   active complex.";
RL   J. Cell Sci. 124:252-260(2011).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [30]
RP   POSSIBLE INVOLVEMENT IN MULTIPLE CONGENITAL ANOMALIES, VARIANT GLY-102, AND
RP   CHARACTERIZATION OF VARIANT GLY-102.
RX   PubMed=22267179; DOI=10.1002/humu.22027;
RA   Kitazawa S., Kondo T., Mori K., Yokoyama N., Matsuo M., Kitazawa R.;
RT   "A p.D116G mutation in CREB1 leads to novel multiple malformation syndrome
RT   resembling CrebA knockout mouse.";
RL   Hum. Mutat. 33:651-654(2012).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-122, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [34] {ECO:0007744|PDB:2LXT}
RP   STRUCTURE BY NMR OF 102-135 IN COMPLEX WITH KMT2A AND CREBBP.
RX   PubMed=23651431; DOI=10.1021/cb4002188;
RA   Bruschweiler S., Konrat R., Tollinger M.;
RT   "Allosteric communication in the KIX domain proceeds through dynamic
RT   repacking of the hydrophobic core.";
RL   ACS Chem. Biol. 8:1600-1610(2013).
CC   -!- FUNCTION: Phosphorylation-dependent transcription factor that
CC       stimulates transcription upon binding to the DNA cAMP response element
CC       (CRE), a sequence present in many viral and cellular promoters (By
CC       similarity). Transcription activation is enhanced by the TORC
CC       coactivators which act independently of Ser-119 phosphorylation
CC       (PubMed:14536081). Involved in different cellular processes including
CC       the synchronization of circadian rhythmicity and the differentiation of
CC       adipose cells (By similarity). Regulates the expression of apoptotic
CC       and inflammatory response factors in cardiomyocytes in response to
CC       ERFE-mediated activation of AKT signaling (By similarity).
CC       {ECO:0000250|UniProtKB:P27925, ECO:0000250|UniProtKB:Q01147,
CC       ECO:0000269|PubMed:14536081}.
CC   -!- SUBUNIT: Interacts with PPRC1. Binds DNA as a dimer. This dimer is
CC       stabilized by magnesium ions. Interacts, through the bZIP domain, with
CC       the coactivators CRTC1/TORC1, CRTC2/TORC2 and CRTC3/TORC3. When
CC       phosphorylated on Ser-119, binds CREBBP (By similarity). Interacts with
CC       CREBL2; regulates CREB1 phosphorylation, stability and transcriptional
CC       activity (By similarity). Interacts (phosphorylated form) with TOX3.
CC       Interacts with ARRB1. Binds to HIPK2. Interacts with SGK1. Interacts
CC       with TSSK4; this interaction facilitates phosphorylation on Ser-119
CC       (PubMed:15964553). Forms a complex with KMT2A and CREBBP (By
CC       similarity) (PubMed:14506290, PubMed:14536081, PubMed:15454081,
CC       PubMed:15733869, PubMed:15964553, PubMed:16325578, PubMed:16908542,
CC       PubMed:20573984, PubMed:21172805, PubMed:23651431). Interacts with
CC       TOX4; CREB1 is required for full induction of TOX4-dependent activity
CC       and the interaction is increased by cAMP and inhibited by insulin (By
CC       similarity). {ECO:0000250|UniProtKB:Q01147,
CC       ECO:0000269|PubMed:14506290, ECO:0000269|PubMed:14536081,
CC       ECO:0000269|PubMed:15454081, ECO:0000269|PubMed:15733869,
CC       ECO:0000269|PubMed:15964553, ECO:0000269|PubMed:16325578,
CC       ECO:0000269|PubMed:16908542, ECO:0000269|PubMed:20573984,
CC       ECO:0000269|PubMed:21172805, ECO:0000269|PubMed:23651431}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis B virus/HBV
CC       protein X. {ECO:0000269|PubMed:1827531}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HTLV-1 protein Tax.
CC       {ECO:0000269|PubMed:1386673}.
CC   -!- INTERACTION:
CC       P16220; O95994: AGR2; NbExp=3; IntAct=EBI-711855, EBI-712648;
CC       P16220; P18846: ATF1; NbExp=6; IntAct=EBI-711855, EBI-852794;
CC       P16220; P16220: CREB1; NbExp=4; IntAct=EBI-711855, EBI-711855;
CC       P16220; Q92793: CREBBP; NbExp=2; IntAct=EBI-711855, EBI-81215;
CC       P16220; Q6UUV9: CRTC1; NbExp=6; IntAct=EBI-711855, EBI-1644259;
CC       P16220; Q53ET0: CRTC2; NbExp=3; IntAct=EBI-711855, EBI-1181987;
CC       P16220; P42858: HTT; NbExp=3; IntAct=EBI-711855, EBI-466029;
CC       P16220; O00470: MEIS1; NbExp=9; IntAct=EBI-711855, EBI-1210694;
CC       P16220; O95644: NFATC1; NbExp=3; IntAct=EBI-711855, EBI-6907210;
CC       P16220; Q13469: NFATC2; NbExp=2; IntAct=EBI-711855, EBI-716258;
CC       P16220; Q16649: NFIL3; NbExp=3; IntAct=EBI-711855, EBI-3951858;
CC       P16220; Q96RG2: PASK; NbExp=2; IntAct=EBI-711855, EBI-1042651;
CC       P16220; O75928-2: PIAS2; NbExp=3; IntAct=EBI-711855, EBI-348567;
CC       P16220; P78317: RNF4; NbExp=3; IntAct=EBI-711855, EBI-2340927;
CC       P16220; Q6SA08: TSSK4; NbExp=5; IntAct=EBI-711855, EBI-1202583;
CC       P16220; P0C746: HBZ; Xeno; NbExp=2; IntAct=EBI-711855, EBI-10890294;
CC       P16220; Q9DGW5: MDV005; Xeno; NbExp=2; IntAct=EBI-711855, EBI-10889526;
CC       P16220; P03259-2; Xeno; NbExp=2; IntAct=EBI-711855, EBI-7225021;
CC       P16220-1; Q09472: EP300; NbExp=2; IntAct=EBI-26386865, EBI-447295;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00312,
CC       ECO:0000255|PROSITE-ProRule:PRU00978, ECO:0000269|PubMed:12552083}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=CREB-B;
CC         IsoId=P16220-2; Sequence=Displayed;
CC       Name=2; Synonyms=CREB-A;
CC         IsoId=P16220-1; Sequence=VSP_060702;
CC       Name=3; Synonyms=htCREB;
CC         IsoId=P16220-3; Sequence=VSP_060702, VSP_060703;
CC   -!- PTM: Stimulated by phosphorylation. Phosphorylation of both Ser-119 and
CC       Ser-128 in the SCN regulates the activity of CREB and participates in
CC       circadian rhythm generation. Phosphorylation of Ser-119 allows CREBBP
CC       binding. In liver, phosphorylation is induced by fasting or glucagon in
CC       a circadian fashion (By similarity). CREBL2 positively regulates
CC       phosphorylation at Ser-119 thereby stimulating CREB1 transcriptional
CC       activity (By similarity). Phosphorylated upon calcium influx by CaMK4
CC       and CaMK2 on Ser-119. CaMK4 is much more potent than CaMK2 in
CC       activating CREB. Phosphorylated by CaMK2 on Ser-128. Phosphorylation of
CC       Ser-128 blocks CREB-mediated transcription even when Ser-119 is
CC       phosphorylated. Phosphorylated by CaMK1 (By similarity).
CC       Phosphorylation of Ser-257 by HIPK2 in response to genotoxic stress
CC       promotes CREB1 activity, facilitating the recruitment of the
CC       coactivator CBP. Phosphorylated at Ser-119 by RPS6KA3, RPS6KA4 and
CC       RPS6KA5 in response to mitogenic or stress stimuli. Phosphorylated by
CC       TSSK4 on Ser-119 (PubMed:15964553). {ECO:0000250,
CC       ECO:0000269|PubMed:15733869, ECO:0000269|PubMed:15964553,
CC       ECO:0000269|PubMed:20573984, ECO:0000269|PubMed:7608156,
CC       ECO:0000269|PubMed:8065343, ECO:0000269|PubMed:9770464,
CC       ECO:0000269|PubMed:9829964}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylation on Lys-290, but not on Lys-271,
CC       is required for nuclear localization of this protein. Sumoylation is
CC       enhanced under hypoxia, promoting nuclear localization and
CC       stabilization. {ECO:0000269|PubMed:12552083}.
CC   -!- DISEASE: Angiomatoid fibrous histiocytoma (AFH) [MIM:612160]: A
CC       distinct variant of malignant fibrous histiocytoma that typically
CC       occurs in children and adolescents and is manifest by nodular
CC       subcutaneous growth. Characteristic microscopic features include
CC       lobulated sheets of histiocyte-like cells intimately associated with
CC       areas of hemorrhage and cystic pseudovascular spaces, as well as a
CC       striking cuffing of inflammatory cells, mimicking a lymph node
CC       metastasis. Note=The gene represented in this entry may be involved in
CC       disease pathogenesis. A chromosomal aberration involving CREB1 is found
CC       in a patient with angiomatoid fibrous histiocytoma. Translocation
CC       t(2;22)(q33;q12) with CREB1 generates a EWSR1/CREB1 fusion gene that is
CC       most common genetic abnormality in this tumor type.
CC   -!- DISEASE: Note=A CREB1 mutation has been found in a patient with
CC       multiple congenital anomalies consisting of agenesis of the corpus
CC       callosum, cerebellar hypoplasia, severe neonatal respiratory distress
CC       refractory to surfactant, thymus hypoplasia, and thyroid follicular
CC       hypoplasia. {ECO:0000269|PubMed:22267179}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Highly expressed in adult testis and sperm.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the bZIP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S72459; AAB20597.1; -; Genomic_DNA.
DR   EMBL; X55545; CAA39151.1; -; mRNA.
DR   EMBL; M34356; AAA35717.1; -; mRNA.
DR   EMBL; M34356; AAA35716.1; -; mRNA.
DR   EMBL; M27691; AAA35715.1; -; mRNA.
DR   EMBL; X60003; CAA42620.1; -; mRNA.
DR   EMBL; AY347527; AAQ24858.1; -; mRNA.
DR   EMBL; BC010636; AAH10636.1; -; mRNA.
DR   EMBL; S53724; AAD13869.1; -; Genomic_DNA.
DR   CCDS; CCDS2374.1; -. [P16220-2]
DR   CCDS; CCDS2375.1; -. [P16220-1]
DR   PIR; A37340; A35769.
DR   PIR; B37340; B35769.
DR   PIR; S22298; S22298.
DR   RefSeq; NP_001358355.1; NM_001371426.1. [P16220-1]
DR   RefSeq; NP_001358356.1; NM_001371427.1. [P16220-2]
DR   RefSeq; NP_004370.1; NM_004379.5. [P16220-2]
DR   RefSeq; NP_604391.1; NM_134442.5. [P16220-1]
DR   RefSeq; XP_011508947.1; XM_011510645.1.
DR   RefSeq; XP_011508949.1; XM_011510647.2.
DR   RefSeq; XP_047299391.1; XM_047443435.1. [P16220-1]
DR   RefSeq; XP_054196588.1; XM_054340613.1. [P16220-1]
DR   PDB; 2LXT; NMR; -; C=102-135.
DR   PDB; 5ZK1; X-ray; 3.05 A; A=269-327.
DR   PDB; 5ZKO; X-ray; 3.05 A; A/C=269-327.
DR   PDB; 7TBH; EM; 2.30 A; a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x=114-132.
DR   PDBsum; 2LXT; -.
DR   PDBsum; 5ZK1; -.
DR   PDBsum; 5ZKO; -.
DR   PDBsum; 7TBH; -.
DR   AlphaFoldDB; P16220; -.
DR   BMRB; P16220; -.
DR   SMR; P16220; -.
DR   BioGRID; 107775; 240.
DR   ComplexPortal; CPX-2494; bZIP transcription factor complex, BACH1-CREB1.
DR   ComplexPortal; CPX-6405; bZIP transcription factor complex, ATF1-CREB1.
DR   ComplexPortal; CPX-8; bZIP transcription factor complex, ATF4-CREB1.
DR   CORUM; P16220; -.
DR   DIP; DIP-765N; -.
DR   FunCoup; P16220; 7373.
DR   IntAct; P16220; 138.
DR   MINT; P16220; -.
DR   STRING; 9606.ENSP00000387699; -.
DR   ChEMBL; CHEMBL5587; -.
DR   DrugBank; DB00131; Adenosine phosphate.
DR   DrugBank; DB01183; Naloxone.
DR   GlyCosmos; P16220; 6 sites, 2 glycans.
DR   GlyGen; P16220; 7 sites, 3 O-linked glycans (6 sites).
DR   iPTMnet; P16220; -.
DR   MetOSite; P16220; -.
DR   PhosphoSitePlus; P16220; -.
DR   SwissPalm; P16220; -.
DR   BioMuta; CREB1; -.
DR   DMDM; 117434; -.
DR   jPOST; P16220; -.
DR   MassIVE; P16220; -.
DR   PaxDb; 9606-ENSP00000387699; -.
DR   PeptideAtlas; P16220; -.
DR   ProteomicsDB; 53324; -. [P16220-1]
DR   ProteomicsDB; 53325; -. [P16220-2]
DR   ProteomicsDB; 53326; -. [P16220-3]
DR   Pumba; P16220; -.
DR   ABCD; P16220; 1 sequenced antibody.
DR   Antibodypedia; 3536; 2200 antibodies from 53 providers.
DR   DNASU; 1385; -.
DR   Ensembl; ENST00000353267.8; ENSP00000236995.3; ENSG00000118260.15. [P16220-2]
DR   Ensembl; ENST00000430624.5; ENSP00000405539.1; ENSG00000118260.15. [P16220-2]
DR   Ensembl; ENST00000432329.6; ENSP00000387699.2; ENSG00000118260.15. [P16220-1]
DR   GeneID; 1385; -.
DR   KEGG; hsa:1385; -.
DR   MANE-Select; ENST00000353267.8; ENSP00000236995.3; NM_004379.5; NP_004370.1.
DR   AGR; HGNC:2345; -.
DR   CTD; 1385; -.
DR   DisGeNET; 1385; -.
DR   GeneCards; CREB1; -.
DR   HGNC; HGNC:2345; CREB1.
DR   HPA; ENSG00000118260; Low tissue specificity.
DR   MalaCards; CREB1; -.
DR   MIM; 123810; gene.
DR   MIM; 612160; phenotype.
DR   OpenTargets; ENSG00000118260; -.
DR   Orphanet; 97338; Melanoma of soft tissue.
DR   VEuPathDB; HostDB:ENSG00000118260; -.
DR   eggNOG; KOG3584; Eukaryota.
DR   GeneTree; ENSGT00940000155408; -.
DR   InParanoid; P16220; -.
DR   OMA; TIAQVSM; -.
DR   OrthoDB; 5970722at2759; -.
DR   PAN-GO; P16220; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; P16220; -.
DR   PathwayCommons; P16220; -.
DR   Reactome; R-HSA-111931; PKA-mediated phosphorylation of CREB. [P16220-1]
DR   Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. [P16220-1]
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus. [P16220-1]
DR   Reactome; R-HSA-199920; CREB phosphorylation. [P16220-1]
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis. [P16220-1]
DR   Reactome; R-HSA-2197563; NOTCH2 intracellular domain regulates transcription. [P16220-1]
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. [P16220-1]
DR   Reactome; R-HSA-400253; Circadian Clock. [P16220-1]
DR   Reactome; R-HSA-442720; CREB1 phosphorylation through the activation of Adenylate Cyclase. [P16220-1]
DR   Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. [P16220-1]
DR   Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. [P16220-1]
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. [P16220-1]
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK. [P16220-1]
DR   Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity. [P16220-1]
DR   Reactome; R-HSA-9022699; MECP2 regulates neuronal receptors and channels. [P16220-1]
DR   Reactome; R-HSA-9022702; MECP2 regulates transcription of neuronal ligands. [P16220-1]
DR   Reactome; R-HSA-9022707; MECP2 regulates transcription factors. [P16220-1]
DR   Reactome; R-HSA-9031628; NGF-stimulated transcription. [P16220-1]
DR   Reactome; R-HSA-9609690; HCMV Early Events. [P16220-1]
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis. [P16220-1]
DR   Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. [P16220-1]
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production. [P16220-1]
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis. [P16220-1]
DR   Reactome; R-HSA-9707616; Heme signaling. [P16220-1]
DR   Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation. [P16220-1]
DR   Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. [P16220-1]
DR   SignaLink; P16220; -.
DR   SIGNOR; P16220; -.
DR   BioGRID-ORCS; 1385; 41 hits in 1190 CRISPR screens.
DR   ChiTaRS; CREB1; human.
DR   EvolutionaryTrace; P16220; -.
DR   GeneWiki; CREB1; -.
DR   GenomeRNAi; 1385; -.
DR   Pharos; P16220; Tbio.
DR   PRO; PR:P16220; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P16220; protein.
DR   Bgee; ENSG00000118260; Expressed in secondary oocyte and 215 other cell types or tissues.
DR   ExpressionAtlas; P16220; baseline and differential.
DR   GO; GO:1990589; C:ATF4-CREB1 transcription factor complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000791; C:euchromatin; IDA:BHF-UCL.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ComplexPortal.
DR   GO; GO:1990763; F:arrestin family protein binding; IEA:Ensembl.
DR   GO; GO:0035497; F:cAMP response element binding; IDA:BHF-UCL.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:MGI.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IEA:Ensembl.
DR   GO; GO:0030544; F:Hsp70 protein binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0001223; F:transcription coactivator binding; IEA:Ensembl.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0141156; P:cAMP/PKA signal transduction; IDA:MGI.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl.
DR   GO; GO:1904322; P:cellular response to forskolin; IDA:MGI.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL.
DR   GO; GO:0071294; P:cellular response to zinc ion; IEA:Ensembl.
DR   GO; GO:0034670; P:chemotaxis to arachidonate; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0046879; P:hormone secretion; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0060430; P:lung saccule development; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IDA:BHF-UCL.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0055025; P:positive regulation of cardiac muscle tissue development; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0046887; P:positive regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:1904181; P:positive regulation of membrane depolarization; IEA:Ensembl.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0032916; P:positive regulation of transforming growth factor beta3 production; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0050821; P:protein stabilization; ISS:UniProtKB.
DR   GO; GO:0008361; P:regulation of cell size; IEA:Ensembl.
DR   GO; GO:0048145; P:regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0060251; P:regulation of glial cell proliferation; IEA:Ensembl.
DR   GO; GO:2000224; P:regulation of testosterone biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:ComplexPortal.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:1903494; P:response to dehydroepiandrosterone; IEA:Ensembl.
DR   GO; GO:0036017; P:response to erythropoietin; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0033762; P:response to glucagon; ISS:UniProtKB.
DR   GO; GO:1990910; P:response to hypobaric hypoxia; IEA:Ensembl.
DR   GO; GO:1902065; P:response to L-glutamate; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0014074; P:response to purine-containing compound; IDA:MGI.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0033363; P:secretory granule organization; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0060509; P:type I pneumocyte differentiation; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   CDD; cd14690; bZIP_CREB1; 1.
DR   DisProt; DP02003; -.
DR   FunFam; 1.20.5.170:FF:000003; cAMP-responsive element modulator isoform X2; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   IDEAL; IID00442; -.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR046347; bZIP_sf.
DR   InterPro; IPR003102; CREB1-like_pKID.
DR   InterPro; IPR001630; Leuzip_CREB.
DR   PANTHER; PTHR45879; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN B; 1.
DR   PANTHER; PTHR45879:SF1; CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN 1; 1.
DR   Pfam; PF00170; bZIP_1; 1.
DR   Pfam; PF02173; pKID; 1.
DR   PRINTS; PR00041; LEUZIPPRCREB.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF57959; Leucine zipper domain; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
DR   PROSITE; PS50953; KID; 1.
DR   neXtProt; NX_P16220; -.
DR   PharmGKB; PA26864; -.
DR   TreeFam; TF106464; -.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Biological rhythms;
KW   Chromosomal rearrangement; Differentiation; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..327
FT                   /note="Cyclic AMP-responsive element-binding protein 1"
FT                   /id="PRO_0000076597"
FT   DOMAIN          87..146
FT                   /note="KID"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00312"
FT   DOMAIN          269..327
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          1..26
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          94..113
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          125..148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          270..295
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          297..318
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   SITE            300
FT                   /note="Required for binding TORCs"
FT   MOD_RES         119
FT                   /note="Phosphoserine; by CaMK1, CaMK2, CaMK4, PKB/AKT1 or
FT                   PKB/AKT2, RPS6KA3, RPS6KA4, RPS6KA5, SGK1 and TSSK4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00312,
FT                   ECO:0000269|PubMed:15733869, ECO:0000269|PubMed:15964553,
FT                   ECO:0000269|PubMed:7608156, ECO:0000269|PubMed:8065343,
FT                   ECO:0000269|PubMed:9770464, ECO:0000269|PubMed:9829964"
FT   MOD_RES         128
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         257
FT                   /note="Phosphoserine; by HIPK2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00312,
FT                   ECO:0000269|PubMed:20573984"
FT   CROSSLNK        122
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        271
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000269|PubMed:12552083"
FT   CROSSLNK        290
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000269|PubMed:12552083"
FT   VAR_SEQ         86
FT                   /note="V -> VQSSCKDLKRLFSGT (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_060702"
FT   VAR_SEQ         148..258
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_060703"
FT   VARIANT         102
FT                   /note="D -> G (found in a patient with multiple congenital
FT                   anomalies; does not affect CREB1 phosphorylation at S-119;
FT                   fails to interact with CREBBP; dbSNP:rs387906617)"
FT                   /evidence="ECO:0000269|PubMed:22267179"
FT                   /id="VAR_068077"
FT   MUTAGEN         119
FT                   /note="S->A: Does not interact with TOX3 and inhibits
FT                   induction of transcription by TOX3. Loss of phosphorylation
FT                   by CaMK4. Loss of phosphorylation by TSSK4."
FT                   /evidence="ECO:0000269|PubMed:15964553,
FT                   ECO:0000269|PubMed:21172805, ECO:0000269|PubMed:8065343"
FT   MUTAGEN         141
FT                   /note="K->R: No effect on sumoylation."
FT                   /evidence="ECO:0000269|PubMed:12552083"
FT   MUTAGEN         257
FT                   /note="S->A: Impaired phosphorylation by HIPK2 and
FT                   subsequent transactivation."
FT                   /evidence="ECO:0000269|PubMed:20573984"
FT   MUTAGEN         257
FT                   /note="S->E: Potentiated transactivation."
FT                   /evidence="ECO:0000269|PubMed:20573984"
FT   MUTAGEN         271
FT                   /note="K->R: Decreased sumoylation, in vivo and in vitro."
FT                   /evidence="ECO:0000269|PubMed:12552083"
FT   MUTAGEN         290
FT                   /note="K->R: Decreased sumoylation, in vivo and in vitro.
FT                   Loss of nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:12552083"
FT   CONFLICT        4
FT                   /note="E -> D (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        8
FT                   /note="E -> D (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        146
FT                   /note="T -> A (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        153
FT                   /note="T -> A (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        155
FT                   /note="T -> A (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        162
FT                   /note="Q -> R (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        170
FT                   /note="A -> T (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        174
FT                   /note="G -> R (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        181
FT                   /note="N -> S (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196
FT                   /note="T -> A (in Ref. 5; CAA42620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        278
FT                   /note="K -> E (in Ref. 6; AAQ24858)"
FT                   /evidence="ECO:0000305"
FT   HELIX           106..114
FT                   /evidence="ECO:0007829|PDB:2LXT"
FT   HELIX           118..130
FT                   /evidence="ECO:0007829|PDB:7TBH"
FT   HELIX           272..322
FT                   /evidence="ECO:0007829|PDB:5ZK1"
SQ   SEQUENCE   327 AA;  35136 MW;  F5BA8200EE5184B7 CRC64;
     MTMESGAENQ QSGDAAVTEA ENQQMTVQAQ PQIATLAQVS MPAAHATSSA PTVTLVQLPN
     GQTVQVHGVI QAAQPSVIQS PQVQTVQIST IAESEDSQES VDSVTDSQKR REILSRRPSY
     RKILNDLSSD APGVPRIEEE KSEEETSAPA ITTVTVPTPI YQTSSGQYIA ITQGGAIQLA
     NNGTDGVQGL QTLTMTNAAA TQPGTTILQY AQTTDGQQIL VPSNQVVVQA ASGDVQTYQI
     RTAPTSTIAP GVVMASSPAL PTQPAEEAAR KREVRLMKNR EAARECRRKK KEYVKCLENR
     VAVLENQNKT LIEELKALKD LYCHKSD
//
